Still Have Questions?
If you did not find an answer to your question, please contact us to speak with an expert:
Business days: 8 AM - 4 PM ET
Videos
Training Video: Handling iCell Cardiomyocytes
This training video shows the proper techniques for storing, thawing, seeding, plating and maintaining iCell® Cardiomyocytes for use in your intended assays. Please contact Cellular Dynamics Technical Support for additional questions about these cells, and their proper handling and use in your assay application.
(Oct 21, 2011)
Electrophysiology of hiPSC-derived Cardiomyocytes
From: The Podcast Series for AJP – Heart and Circulatory Physiology
The discovery of induced pluripotent stem (iPS) cells has allowed researchers to generate human cardiomyocytes from patients. Why is this important? Human iPS cells are useful for studying normal and diseased human cardiomyocytes and for discovering new drug therapies to treat cardiovascular disease. Until now, methods for generating cardiomyocytes from human iPS or ES cells were inconsistent and often unreliable. The recent article by Ma et al presents a new method to obtain a large quantity of cultured cardiac myocytes using embryoid body formation and blasticidin selection techniques resulting in more than 98% purity from human iPS cell lines. Associate Editor Junichi Sadoshima talks with authors Craig January (University of Wisconsin – Madison) and Brad Swanson (Cellular Dynamics International), along with leading expert Diego Fraidenraich (University of Medicine and Dentistry, New Jersey), about this groundbreaking research and its many potential applications.
View the Roche video, Arrhythmia Prediction Using iCell® Cardiomyocytes and the xCELLigence RTCA Cardio System
Ion channel block is detected as irregular contractile activity in the hCAR Assay. iCell Cardiomyocytes were plated as a confluent monolayer and exposed to 0.03 mM of the hERG channel blocking agent, E-4031. The video shows the rhythmic contractile activity of the cardiomyocytes under control conditions (pre-drug) and the arrhythmic activity following drug application (E-4031 0.03 mM). Courtesy of Hoffmann-La Roche
Still Have Questions?
If you did not find an answer to your question, please contact us to speak with an expert:
Business days: 8 AM - 4 PM ET
